Telehealth Giant Hims & Hers Soars 40% Following Weight-Loss Drug Deal with Novo Nordisk
Telehealth titan Hims & Hers Health experienced a staggering 40% surge in its stock on Monday. This followed the announcement of a pivotal partnership with pharmaceutical powerhouse Novo Nordisk, effectively ending a contentious legal dispute between the two companies.
As part of the agreement, Hims & Hers will provide FDA-approved Ozempic and Wegovy medications, including the newly introduced Wegovy pill, via its telehealth platform. In return, the company will halt advertising and marketing of compounded versions of GLP-1 weight-loss drugs, which had previously been a significant point of contention between the two entities.
Novo Nordisk has withdrawn its patent infringement lawsuit against Hims & Hers. However, the Danish pharmaceutical firm retains the right to refile in the future. Novo Nordisk President and CEO Mike Doustdar commented, “This agreement with Hims & Hers is a significant victory for patients in the United States.” This collaboration signifies a remarkable shift from their previous partnership that fell apart in 2025 when Hims & Hers refused to cease selling compounded versions of semaglutide.
The agreement eliminates a substantial regulatory burden for Hims & Hers and grants the company legitimate access to the world’s most sought-after weight-loss medications. The company’s shares closed at $22.15, up 40.72%, with trading volume hitting 168.1 million shares—approximately 557% above its three-month average.
Source: CNBC